Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.

doi:10.1158/1078-0432.CCR-19-1844

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2020

Ivanova Elena, Kuraguchi Mari, Xu Man, Portell Andrew J, Taus Luke, Diala Irmina, Lalani Alshad S, Choi Jihyun, Chambers Emily S, Li Shuai, Liu Shengwu, Chen Ting, Barbie Thanh U, Oxnard Geoffrey R, Haworth Jacob J, Wong Kwok-Kin, Dahlberg Suzanne E, Aref Amir A, Barbie David A, Bahcall Magda, Paweletz Cloud P, Jänne Pasi A

Abstract excerpt

PURPOSE: Evaluating drug responses using primary patient-derived cells ex vivo represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in HER2 mutant non-small cell lung cancer (NSCLC) patient xenograft-derived organotypic spheroids (XDOTS) using a short-term ex vivo system. EXPERIMENTAL DESIGN: We generated two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Quinolines

Share to Receptor, ErbB-2

Share to Spheroids, Cellular

Share to Trastuzumab

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32034078
DOI: 10.1158/1078-0432.CCR-19-1844
PMCID: PMC7967092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.PMID 32034078Read ↗

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and OrganoidsSemantic proximity Read ↗

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsSemantic proximity Read ↗

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.Semantic proximity Read ↗

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read ↗

Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.Semantic proximity Read ↗

Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancerSemantic proximity Read ↗

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.Semantic proximity Read ↗

A dual-functional microfluidic chip for guiding personalized lung cancer medicine: combining EGFR mutation detection and organoid-based drug response test.Semantic proximity Read ↗

Patient-derived organoids of non-small cells lung cancer and their application for drug screeningSemantic proximity Read ↗

Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients.Semantic proximity Read ↗

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.Semantic proximity Read ↗

Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.